Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004915 · ClinicalTrials.gov registry record · Phase 2
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004915: Completed Phase 2 study, sponsored by Northwestern University.
NCT00004915 is a Phase 2 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004915, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.
Interventions
- DRUG raloxifene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2000-02 |
| Phase | Phase 2 |
What the finished NCT00004915 record still lists
NCT00004915 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which raloxifene is the first listed.
NCT00004915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004915 about?
NCT00004915 is a clinical study titled "Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer". RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endo...
What is the current status of trial NCT00004915?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2000-02.
What interventions are being tested in trial NCT00004915?
The interventions under investigation include: raloxifene (DRUG).
Who is sponsoring clinical trial NCT00004915?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia